Hydroxyurea in the management of thalassemia intermedia

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Karimi, Mehran ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; DROXIA; HEMOGLOBIN F; HYDROXYUREA; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ALOPECIA; ANOREXIA; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSTIPATION; CONVULSION; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DYSURIA; ENERGY RECOVERY; ERYTHEMA; EXTRAMEDULLARY HEMATOPOIESIS; FATIGUE; FEVER; FIBROSIS; GANGRENE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERPYREXIA; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LIVER FAILURE; LOW DRUG DOSE; MEGALOBLASTIC ANEMIA; NAUSEA; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PSORIASIS; RADIATION SICKNESS; SERUM SICKNESS; SICKLE CELL ANEMIA; SIDE EFFECT; SKELETON MALFORMATION; SKIN CANCER; SKIN ULCER; SPLENOMEGALY; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; UREA NITROGEN BLOOD LEVEL; VASCULITIS; VOMITING;

ANTINEOPLASTIC AGENTS; BETA-THALASSEMIA; HEMOGLOBINS; HUMANS; HYDROXYUREA; TREATMENT OUTCOME;

EID: 73949111281     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903351809     Document Type: Conference Paper

References (13)

1. Katzung B, Masters S, Trevor A. Basic and Clinical Pharmacology, 11th Edition. 2009.
2. Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83(5):366-370.
3. Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol. 2001;40(8):530-534.
4. Biron F, Ponceeau B, Bouhour D, Boibieux A, Verrier B, Peyramond D. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. J Acquir Immune Defic Syndr. 2000;25(4):329-336.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
6. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102(4): 1529-1530.
7. Yavarian M, Karimim M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica. 2004;89(10): 1172-1178.
8. Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830-1836.
9. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380-385.
10. Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, et al. Hydroxyurea in thalassemia intermedia--a promising therapy. Ann Hematol. 2005;84(7):441-446
11. Mancuso A, Maggio A, Renda D, Di Marzo R, Rigano P. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br J Haematol. 2006;133(1):105-106
12. Gamberini MR, Fortini M, De Sanctis V. Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatr Endocrinol Rev. 2004;Suppl 2:319-322
13. Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol. 2009;82(3):213-218.